**Variability within the human iNOS gene and Achilles tendon injuries: Evidence for a heterozygous advantage effect**

**Abstract**

Objectives: The aim of this case control genetic association study was to explore whether two variants within the inducible nitric oxide synthase (iNOS) gene, rs2779249 (C/A) and rs2248814 (A/G), inﬂuenced the risk of Achilles tendinopathy in a British population.

Design: Candidate gene, case control association study.

Method: We recruited 145 individuals diagnosed with Achilles tendon pathology and 132 asymptomatic controls. All participants were genotyped for the iNOS variants using qPCR and signiﬁcant associations were discovered using a combination of Chi squared and ANOVA type analysis.

Results: The CA genotype of the iNOS rs2779249 variant was protective and conformed to a heterozygous advantage model of inheritance as it was overrepresented in the control participants (p = 0.009). In sex speciﬁc analysis the protective association persisted in male participants (p = 0.016) but not in females. Unlike the rs2779249 variant, the rs2248814 variant was not associated with Achilles tendinopathy or Achilles tendon rupture.

Conclusion: The rs2779249 CA genotype within the human iNOS gene appears to protect individuals from Achilles tendinopathy. This study further supports a genetic contribution to modifying the risk of Achilles tendon problems. The study also infers an important role for nitric oxide in tendon healing and/or degradation

**Practical implications**

• The iNOS rs2779249 genotype could be used to assess risk of Achilles tendon problems in athletic populations.

• The iNOS rs2779249 genotype might have future application in

personalised treatments for those with Achilles tendon pathologies.

• The inclusion of the iNOS rs2779249 genotype in current injury

risk models might improve the predictive potential of such tests to assess risk.

**Introduction**

Achilles tendon pathology (ATP) is a complex, painful, degenerative condition, affecting both sporting and sedentary individuals.1 75% of Achilles tendon ruptures are observed in middle aged sport participating males.2 Multiple intrinsic and extrinsic risk factors contribute to ATP aetiology, and the condition is known to have a genetic3 and, more recently, an epigenetic basis.4,5

The inducible nitric oxide synthase (iNOS) gene is one of three Nitric Oxide Synthase (NOS) genes (eNOS, nNOS, iNOS)6 responsible for nitric oxide (NO) generation through L arginine oxidation and catalysed by the NOS enzymes.7 NO is a free radical and is associated with multiple biological functions.8 After tendon injury, NO is induced by all 3 NOS isoforms, with upregulated NOS activity reported in tendinopathy in both human and rat models.6 Research suggests that iNOS expression is elevated 23 fold higher than controls four days after Achilles tendon injury.9 Lin et al.9 suggest that NO catalysed by the iNOS isoform of NOS induces apoptosis in inﬂammatory cells to eradicate the cells from the damaged area, preventing chronic inﬂammation and allowing remodelling to occur.

An iNOS gene transfection study demonstrated NO’s ability to enhance collagen synthesis in tendon cells in vitro.10 The increased collagen synthesis was inhibited when a NOS inhibitor was employed. The use of glyceryl trinitrate (GTN) patches containing NO, in conjunction with rehabilitation, has been studied in a randomised group of patients with Achilles tendinopathy in comparison to rehabilitation alone.11 It was observed that the addition of the GTN patch signiﬁcantly enhanced patient recovery, with 78% of tendons in the GTN group asymptomatic with daily activities as opposed to 49% in the placebo group (p = 0.001). The addition of GTN patches to patient rehabilitation resulted in reduce pain with activity, and patients presented with lower pain scores after performing a hop test.

In a rat healing model, the administration of NO paracetamol vs two control groups (paracetamol group and a vehicle group) was investigated.12 Paracetamol had no effect on healing when compared to the vehicle group. NO paracetamol vs paracetamol alone displayed similar failure loads, however, secondary end- points of Achilles tendon healing differed between the two groups. At day 10 postoperatively, the NO paracetamol group displayed a smaller cross sectional area, a greater dry weight and lesser wet weight, a larger collagen content and better organization of colla- gen, suggesting the addition of NO increased collagen synthesis and encouraged collagen reorganisation12.

Two iNOS single nucleotide polymorphisms (SNPs) rs2779249 (C/A) and rs2248814 (A/G) were of interest for this study. These variants are situated within the iNOS gene and its 5, ﬂanking region on chromosome 17. The rs2779249 SNP is a functional variant 1026 bp upstream of the promoter region.13 The C allele leads to a 4.73 fold lower transcriptional activity of the promoter compared to the A allele.14 The rs2248814 SNP resides 28,260 bp downstream of the rs2779249 SNP within the intronic region ﬂanked by exons 12 and 13. The rs2248814 SNP has been linked to impaired fracture healing.15 Sathyendra et al.15 looked at sixty two patients with long bone fractures, thirty three presenting with an atrophic nonunion (case group) and twenty nine showing uneventful fracture union (control group). The G allele was found to associate with more than

twice the risk of non-union after fracture.15

As NO plays an important role in collagen homeostasis within the tendon, we hypothesised that genetic variability in NO synthesising genes like iNOS could impact on the risk of tendon injuries. In order to test this hypothesis, we investigated the two SNPs in a British case control population.

**Methods**

145 Caucasian case (ATP) subjects (56 females, 89 males) were originally recruited from the County Clinic, Northampton. The subjects’ pathologies were diagnosed using published criteria pre- viously described for this cohort and assessed by the clinical author (WJR).16 This was based on clinical assessment and conﬁrmed with the appropriate imaging modalities. Those patients considered for certain management techniques, such as high-volume stripping, or for conﬁrmation of rupture underwent ultrasound. Others under- went MRI analysis. For the purpose of our study, the cohort was subdivided into a rupture subset and a chronic tendinopathy sub- set. For clinical management, the patients were further subdivided into complete ruptures, partial ruptures, tendinosis, and para- tendinopathy, however, these are outside the scope of this paper.

We used the abbreviation ATP to describe a set of combined Achilles tendon pathologies. Speciﬁcally, the ATP case participant group consisted of an Achilles tendinopathy subset (TEN) (n = 103) and an Achilles rupture subset (RUP) (n = 42). The RUP subset included subjects with partial or complete ruptures to the Achilles tendon. Full details of the speciﬁc pathological deﬁnitions for this cohort have previously been published.17 In addition to the cases, 132 asymptomatic, healthy, Caucasian control (CON) participants (49 female, 83 male) were recruited from various sports clubs within the East Midlands region of the United Kingdom.

DNA from all participants was isolated as described in our previous study.16 For this study were analysed those same samples using TaqMan® SNP genotyping probes, along with speciﬁc forward and reverse primers, for the iNOS gene rs2779249 and rs2248814 SNPs. Each reaction contained 10 ng of DNA and each PCR plate

contained both positive (repeated samples) and negative (non-template) controls. Following a holding phase at 95 ◦C for 10 min, PCR runs consisted of 40 cycles of a denaturing stage at 92 ◦C for 15 s and a ﬁnal annealing stage at 60 ◦C for 1 min. Genotypes for each sample were determined by end point ﬂuorescence and called using StepOne software v2.1.

IBM SPSS Statistics version 22 (IBM Corporation, Armonk, New York) was used to carry out independent T tests on the participants characteristics (age, BMI, height and weight) between the ATP and CON groups, alongside analysis of variance (ANOVA) to determine whether anthropometric data interacted with genotype for both the ATP and CON groups. Pearson’s Chi square analysis or Fisher’s exact test were used to assess differences between allele and genotype distributions for both the rs2779249 and rs2248814 variants within the ATP and CON groups. A similar analysis was conducted to establish whether any associations were speciﬁc to just tendinopathy (TEN) and/or rupture (RUP) (as opposed to the collective pathology of ATP). We also tested whether sex interacted with genotype.

We used the SNPStats online analysis software (available at https://www.snpstats.net/start.htm) to establish whether alleles at either of the two loci investigated deviated from Hardy Weinberg equilibrium (HWE). Inferred haplotype analysis showing estimated relative frequency was also carried out. Haplotype frequencies were measured using an expectation maximisation algorithm. Further details on the software package and the type of analysis conducted has been published.18

Using the Quanto power software (available at http://biostats. usc.edu/cgi-bin/DownloadQuanto.pl) we calculated that our study would have 81% power to detect associations at the 0.05 level of signiﬁcance. All p values reported were unadjusted based on the rationale presented in our previous studies.19

All experimental protocols received ethical approval from the Research Ethics Committee of the Faculty of Health and Society within the University of Northampton, UK. All subjects provided their written informed consent, in accordance with the Declaration of Helsinki, alongside the completion of an extensive medical history questionnaire.

**Results**

There were no statistical differences between the ATP and CON groups in relation to age, (p = 0.264), height (p = 0.067), weight (p = 0.370), and BMI (p = 0.736). The ATP group ages were self reported age at onset of symptoms. There were no anthropometric interactions with the iNOS rs2779249 genotypes (Table 1a); height, CON (p = 0.183), ATP (p = 0.129); weight, CON (p = 0.175), ATP (p = 0.886); age, CON (p = 0.311), ATP (p = 0.606); BMI, CON

(p = 0.330), ATP (p = 0.843). The iNOS rs2248814 genotypes did not associate with weight (Table 1b), CON (p = 0.110), ATP (p = 0.492); age, CON (p = 0.085), ATP (p = 0.713); BMI, CON (p = 0.548), ATP;

(p = 0.440), however the iNOS rs2248814 AG genotype associated with height (p = 0.029) in the CON group, but not the ATP group (p = 0.915). This variant however, did not associate with ATP, tendinopathy or rupture.

Table 1

Represents the participant characteristic ANOVA results for the iNOS rs2779249 variant and iNOS rs2248814 variant, stratiﬁed according to genotype. Signiﬁcance was accepted when p < 0.05. cm: centimetres; kg: kilogrammes; m: metres.

Table 1a: Characteristics of the entire CON and ATP participant groups for the iNOS variant rs2779249 using one-way ANOVA analysis stratiﬁed according to genotype.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | rs2779249 |  | CON |  |  |  | ATP |  | | |
|  |  | AA | AC | CC |  | AA | AC | CC |  |
|  | Age (years) | N | 9 | 54 | 58 |  | 15 | 31 | 72 |  |
|  |  | Mean | 41.67 | 43.30 | 39.91 |  | 40.20 | 44.61 | 43.19 |  |
|  |  | SD±  P value | ±11.72  0.311 | ±13.48 | ±9.62 |  | ±14.56 | ±12.90 | ±14.33 |  |
|  | BMI (kg/m2) | N | 9 | 55 | 57 |  | 14 | 24 | 49 |  |
|  |  | Mean | 24.59 | 25.44 | 26.47 |  | 26.34 | 26.40 | 25.85 |  |
|  |  | SD±  P value | ±3.65  0.330 | ±4.90 | ±4.18 |  | ±5.22 | ±4.53 | ±3.72 |  |
|  | Height (cm) | N | 9 | 55 | 57 |  | 15 | 33 | 71 |  |
|  |  | Mean | 170.89 | 174.07 | 176.74 |  | 171.93 | 169.76 | 173.86 |  |
|  |  | SD±  P value | ±11.96  0.183 | ±10.04 | ±10.45 |  | ±10.31 | ±9.96 | ±9.26 |  |
|  | Weight (kg) | N | 9 | 55 | 58 |  | 14 | 24 | 49 |  |
|  |  | Mean | 73.00 | 78.04 | 83.43 |  | 79.14 | 76.58 | 78.04 |  |
|  |  | SD± | ±19.16 | ±20.38 | ±18.41 |  | ±18.22 | ±17.87 | ±14.62 |  |
| Table 1b: Characteristics of the entire CON and ATP participant groups for the iNOS variant rs2248814 using one-way ANOVA analysis stratiﬁed according to genotype. | | | | | | | | | | |
|  | rs2248814 |  | CON |  |  |  | ATP |  |  |  |
|  |  |  | AA | AG | GG |  | AA | AG | GG |  |
|  | Age (years) | N | 21 | 70 | 32 |  | 23 | 59 | 32 |  |
|  |  | Mean | 38.14 | 41.10 | 45.09 |  | 41.39 | 44.19 | 43.19 |  |
|  |  | SD±  P value | ±9.49  0.085 | ±11.82 | ±11.73 |  | ±16.20 | ±13.37 | ±12.97 |  |
|  | BMI (kg/m2) | N | 21 | 70 | 32 |  | 20 | 36 | 27 |  |
|  |  | Mean SD±  P value | 26.72  ±4.71  0.548 | 25.49  ±4.56 | 25.87  ±4.24 |  | 25.63  ±2.98 | 26.79  ±4.58 | 25.52  ±4.62 |  |
|  | Height (cm) | N | 21 | 70 | 32 |  | 23 | 62 | 31 |  |
|  |  | Mean SD±  P value | 179.67  ±7.90  0.029 | 173.04  ±10.37 | 176.03  ±11.05 |  | 172.52  ±11.79 | 172.68  ±8.65 | 171.77  ±10.48 |  |
|  | Weight (kg)b | N | 21 | 70 | 33 |  | 20 | 36 | 27 |  |
|  |  | Mean SD±  P value | 87.14  ±20.29  0.110 | 77.17  ±19.24 | 81.15  ±18.86 |  | 75.25  ±13.88  +0.4982 | 80.17  ±16.56 | 76.41  ±17.72 |  |

We found that the iNOS rs2779249 CA genotype was over- represented in the CON individuals (protective effect) (p = 0.009; OR = 0.46; CI 0.27–0.79) (Fig. 1a). Similarly, the CA genotype was signiﬁcantly overrepresented in the control participants compared to the TEN subset (p = 0.005; OR = 0.40; CI 0.22–0.74) (Fig. 1b). How- ever, no associations were noted when the Achilles RUP subset participants were investigated and compared to the control participants (p = 0.600).

We observed the CA genotype of the same variant to be over- represented in the male CON participants (p = 0.016; OR = 0.37; CI = 0.18–0.76) (Fig. 1c), signiﬁcantly overrepresented in the male CON participants in comparison to the male TEN subset (p = 0.007; OR = 0.30; CI = 0.13–0.69), but not signiﬁcant in the male RUP subset (p = 0.660). There were no signiﬁcant differences in the genotype distribution for the iNOS variant rs2779249 when only females were compared between the CON and ATP participants (p = 0.350), CON and TEN subset (p = 0.330), and CON and RUP sub- set (p = 0.720).

No signiﬁcant differences were observed in the genotype distribution of the iNOS gene rs2248814 variant within all investigated participant subsets; all CON participants and all ATP participants (p = 0.760); female CON and female ATP participants (p = 0.500); and male CON and male ATP participants (p = 0.910).

There were no deviations from HWE in the investigated participant groups, except where signiﬁcant differences in the genotype distribution were observed (supplementary Table 2). When this is the case, both the mixed participant sample and the CON partici- pant sample remained in HWE, however the ATP participant sample violated HWE. Raw haplotype data between the CON and ATP participant group can be found in supplementary (supplementary Fig. 3). There were no signiﬁcant haplotypic effects observed, global haplotype association p = 0.077. There were no signiﬁcant differences in allele distribution between the entire CON and entire ATP participant groups for both iNOS rs2779249 (C/A) (supplementary Fig. 2a) and rs2248814 (G/A) (supplementary Fig. 2b) variants.

**Discussion**

In this study we found the iNOS rs2779249 variant inﬂuenced the risk of ATP in a British cohort. Speciﬁcally, the CA genotype was enriched in the CON participant group, inferring the genotype as a contributing factor to reducing the risk of ATP. Our results are consistent with the preliminary ﬁndings of a study by Nell et al. in 2012.20 In their study consisting of 78 individuals diagnosed with Achilles tendinopathy, they reported a marginally signiﬁcant protective effect of the CA genotype (p = 0.049). In our study we also assessed for sex differences and observed a signiﬁcant over- representation of the CA genotype in the male CON participant group. However, this was not observed in females. It is important to note that genetic variants observed to associate with complex pathologies are contributing factors to the total risk and are not to be interpreted as directly responsible. Therefore, our data suggests the rs2779249 CA genotype contributes to a reduction in the risk of Achilles tendon injuries.

It is not fully understood why the iNOS rs2779249 CA variant exerts a protective effect against ATP, however NO is an important messenger molecule mediating both inﬂammatory and apoptotic pathways,21 and an appropriate balance of NO is essential for healthy cellular processes.22 It is known that the C allele of the rs2779249 variant is associated with a 4.73 fold lower transcriptional activity than the A allele.14 Possession of the CC genotype may infer a state in which NO levels are limited compared to those with the AA genotype. Therefore, it might be reasonable to assume that heterozygous CA individuals are producing an appropriate amount of NO, which may lower the risk of sustaining a tendon injury, compared to those with the CC or AA genotype who may be producing too little or too much NO respectively.


Dakin et al. investigated Achilles tendon biopsies from patients to determine whether an inﬂammatory process is a feature of Achilles tendinopathy and rupture and observed evidence of chronic inﬂammation.23 Their investigation found complex macrophage activation protein signatures and observed target molecules expressed in patient tissue samples from interferon, NFKB, STAT6 and GCR activation pathways. NFKB’s are known to control the expression of genes involved in cell adhesion, angio- genesis, apoptosis and the cell cycle,24 and the NFKB family are responsible for initiating expression of iNOS25 and therefore are crucial for iNOS regulation.26

iNOS is the predominant enzyme from the NOS family involved in inﬂammation27 and has been described as a downstream inﬂammatory mediator in multiple cell types, including skeletal muscle cells.28 Inducible NO has been highlighted as an important messenger in the regulation of myogenic precursor cell fate and the inﬂammatory response, indicating inﬂammation dependent muscle healing in a damage/regeneration mouse model.28 Also evidencing that iNOS is scarcely expressed in healthy skeletal muscle.28 Animal studies have demonstrated the importance of iNOS in promoting tendon healing following injury.29 From a clinical perspective, there has been interest in the epigenetic modiﬁcation of iNOS activity in controlling symptoms of chronic Achilles tendinopathy. GTN skin patches liberate NO into the local tissues. It has been shown to be effective in several studies in the management of tendinopathy.30

Although we have found that the iNOS rs2779249 CA genotype reduces the risk of ATP, our study does have some limitations. Firstly, although our study is adequately powered to detect associations in the entire cohort, stratifying by sex would have underpowered this analysis and therefore our sex speciﬁc data should be viewed with caution. Secondly, our study is limited to a single ethnic group and should be repeated in a non Caucasian cohort. Finally, it is now known that epigenetic factors play a signiﬁcant part in the predisposition to musculoskeletal injury4 and therefore further studies should examine the role of DNA methylation and histone modiﬁcation in modifying the impact of genotype on the risk of these injuries.

**Conclusion**

In summary, we have identiﬁed the iNOS rs2779249 CA geno- type as a protective factor contributing to reducing the risk of ATP. Although this genotype modiﬁes risk, Achilles tendon injuries are complex and likely to arise from multiple interactions between genetic and environmental factors (epigenetics). This research enhances our current understanding of risk factors for ATP, and the iNOS gene remains a suitable candidate for further investigation regarding tendon pathology.



**Funding**

The University of Northampton.

**Competing interests**

The research team conﬁrm that there are no competing interests.

**Ethics approval**

This research has been approved by the Research Ethics Committee of the Faculty of Health and Society within the University of Northampton, England.

**Acknowledgements**

The author would like to thank Dr Rebecca Rickaby for her involvement in the recruitment of the subjects and phenotypic data collection which has enabled this research.

**Appendix A. Supplementary data**

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jsams.2019.11. 001.

**References**

1. Yasui Y, Tonogai I, Rosenbaum AJ et al. The risk of Achilles tendon rupture in the patients with Achilles tendinopathy: healthcare database analysis in the United States. Biomed Res Int 2017. Available at: https://doi.org/10.1155/2017/7021862. Accessed 21 June 2017.

2. Freedman B, Gordon J, Soslowsky L et al. The Achilles tendon: fundamental properties and mechanisms governing healing. Muscles Ligaments Tendons J 2014; 4(2):245–255.

3. Raleigh SM, Collins M. Gene variants that predispose to Achilles tendon injuries: an update on recent advances, InTech, 2012. Available at: https://dx.doi.org/10. 5772/33927. Accessed 13 May 2019.

4. El Khoury LY, Rickaby R, Samiric T et al. Promoter methylation status of the TIMP2 and ADAMTS4 genes and patellar tendinopathy. J Sci Med Sport 2018; 21(4):378–382. Available at: https://doi.org/10.1016/j.jsams.2017.08.

016. Accessed 15 July 2019.

5. Rickaby R, El Khoury LY, Samiric T et al. Epigenetic status of the human MMP11 gene promoter is altered in patellar tendinopathy. J Sci Med Sport 2019; 18(1):155–159.

6. Bokhari AR, Murrell GAC. The role of nitric oxide in tendon healing. J Shoul- der Elbow Surg 2012; 21(2):238–244. Available at: https://doi.org/10.1016/j.jse. 2011.11.001. Accessed 12 July 2019.

7. Ferrettia E, Tremblay E, Thibault M et al. The nitric oxide synthase 2 pathway is targeted by both pro- and anti-inﬂammatory treatments in the immature human intestine. Nitric Oxide 2017; 66:53–61. Available at: https://doi.org/10. 1016/j.niox.2017.03.003. Accessed 12 July 2019.

8. Soskic´ SS, Dobutovic´ BD, Sudar EM et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc Med J 2011; 5:153–163.

9. Lin JH, Wang M-X, Wei A et al. Temporal expression of nitric oxide synthase iso- forms in healing Achilles tendon. J Orthop Res 2001; 19(1):136–142. Available at: https://doi.org/10.1016/S0736-0266(00)00019-X. Accessed 24 September 2019.

10. Xia W, Szomor Z, Wangm Y. Nitric oxide enhances collagen synthesis in cultured human tendon cells. J Orthop Res 2006; 24(2):159–172. Available at: https://doi. org/10.1002/jor.20060. Accessed 12 July 2019.

11. Paoloni J, Appleyard RC, Nelson J et al. Topical glyceryl trinitrate treatment of chronic noninsertional Achilles tendinopathy. A randomized, double-blind, placebo-controlled trial. J Bone Joint Surg 2004; 86-A(5):916–922.

12. Murrell GAC, Tang G, Appleyard RC et al. Addition of nitric oxide through nitric oxide-paracetamol enhances healing rat Achilles tendon. Clin Orthop Relat R 2008; 466(7):1618–1624. Available at: https://doi.org/10.1007/s11999-008- 0271-y. Accessed 12 July 2019.

13. Nikkari ST, Määttä KM, Kunnas TA. Functional inducible nitric oxide synthase gene variants associate with hypertension. Medicine 2015; 94(46):e1958.

14. Fu L, Zhao Y, Lu J et al. Functional single nucleotide polymorphism-1026C/A of inducible nitric oxide synthase gene with increased YY1-binding afﬁnity is associated with hypertension. J Hypertens 2009; 27(5):991–1000.

15. Sathyendra V, Donahue HJ, Vrana KE et al. Single nucleotide polymorphisms in osteogenic genes in atrophic delayed fracture-healing: a preliminary investigation. J Bone Joint Surg 2014; 96(15):1242–1248.

16. Rickaby R, El Khoury L, Ribbans WJ et al. Variation within three apoptosis asso- ciated genes as potential risk factors for Achilles tendinopathy in a British based case–control cohort. Gene 2015; 571(2):167–171. Available at: https://doi.org/ 10.1016/j.gene.2015.06.010. Accessed 12 July 2019.

17. El Khoury L, Ribbans WJ, Raleigh SM. MMP3 and TIMP2 gene variants as predis- posing factors for Achilles tendon pathologies: attempted replication study in a British case–control cohort. Meta Gene 2016; 9:52–55. Available at: https://doi. org/10.1016/j.mgene.2016.03.007. Accessed 12 July 2019.

18. Solé X, Guinó E, Valls J et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22(15):1928–1929. Available at: https://doi.org/ 10.1093/bioinformatics/btl268. Accessed 7 September 2019.

19. Posthumus M, Collins M, van der Merwe L et al. Matrix metalloproteinase genes on chromosome 11q22 and the risk of anterior cruciate ligament (ACL) rupture. Scand J Med Sci Sports 2011; 22(4):523–533. Available at: https://doi.org/ 10.1111/j.1600-0838.2010.01270.x. Accessed 12 July 2019.

20. Nell E, van der Merwe L, Cook J et al. The apoptosis pathway and the genetic predisposition to Achilles tendinopathy. J Orthop Res 2012; 30(11):1719–1724. Available at: https://doi.org/10.1002/jor.22144. Accessed 12 July 2019.

21. Vannini F, Kashﬁ K, Nath N. The dual role of iNOS in cancer. Redox Biol 2015; 6:334–343. Available at: https://doi.org/10.1016/j.redox.2015.08.009. Accessed 12 July 2019.

22. Kim J-E, Tannenbaum SR. S-Nitrosation regulates the activation of endogenous procaspase-9 in HT-29 human colon carcinoma cells. J Biol Chem 2004; 279:9758–9764.

23. Dakin SG, Newton J, Martinez FO et al. Chronic inﬂammation is a feature of Achilles tendinopathy and rupture. Br J Sports Med 2018; 52:359–367. Available at: https://doi.org/10.1136/bjsports-2017-098161. Accessed 12 July 2019.

24. Yeung F, Hoberg JE, Ramsey CS et al. Modulation of NF-KB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23(12):2369–2380. Available at: https://doi.org/10.1038/sj.emboj.7600244. Accessed 12 July 2019.

25. Simon PS, Sharman SK, Lu C et al. The NF-KB p65 and p50 homodimer cooperate with IRF8 to activate iNOS transcription. BMC Cancer 2015. Available at: https:// doi.org/10.1186/s12885-015-1808-6. Accessed 3 September 2018.

26. Kijeong K. Interaction between HSP 70 and iNOS in skeletal muscle injury and repair. J Exerc Rehabil 2015; 11(5):240–243. Available at: https://doi.org/10. 12965/jer.150235. Accessed 12 July 2019.

27. Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inﬂamma- tory diseases. J Mol Med 2000; 6(5):347–373.

28. Nakazawa H, Chang K, Shinozaki S et al. iNOS as a driver of Inﬂammation and apoptosis in mouse skeletal muscle after burn injury: possible involvement of sirt1 s-nitrosylation-mediated acetylation of p65 NF-KB and p53. PLoS One 2017. Available at: https://doi.org/10.1371/journal.pone.0170391. Accessed 5 September 2018.

29. Murrell GAC. Using nitric acid to treat tendinopathy. BJSM 2007; 41(4):227–231. Available at: https://doi.org/10.1136/bjsm.2006.034447. Accessed 12 September 2019.

30. Challoumas D, Kirwan PD, Borysov D, Clifford C, McLean M, Millar NL. Topical glyceryl trinitrate for the treatment of tendinopathies: a systematic review. BJSM 2019; 53(4):251–262. Available at: https://doi.org/10.1136/ bjsports-2018-099552. Accessed 12 September 2019.